Claris Injectables Limited began as a wholly-owned subsidiary of Claris Lifesciences Limited. In 2017, Claris Injectables was acquired by Baxter International (Baxter), a global medical products company.
Claris Injectables formulates, fills and finishes a broad portfolio of essential generic medicines with complementary strengths in anesthesia and analgesics, critical care and renal medicines and anti-infectives—including antibiotics, antiprotozoals, antifungals and antivirals—in a variety of presentations including bags, vials and ampoules.
Claris Injectables’ world-class manufacturing facilities include two fill/finish plants and one API plant. One fill/finish plant is registered with a number of global regulatory agencies including the FDA (U.S.), MHRA (UK), TGA (Australia) and ANVISA (Brazil), among others. The second fill/finish plant is registered with MHRA, TGA and ANVISA, and the API plant is registered with the FDA.
With Baxter’s support, Claris Injectables intends to invest in capacity and capabilities to create greater value, including adding new aseptic manufacturing and lyophilization capabilities, new technology platforms in areas like cytotoxics, aseptic development and complex formulations, and an expanded R&D footprint to significantly increase pipeline output and portfolio breadth.